Cytokinetics (CYTK) PT Lowered to $18 at Piper Jaffray

November 21, 2017 11:20 AM EST Send to a Friend
Piper Jaffray lowered its price target on Cytokinetics (NASDAQ: CYTK) to $18.00 (from $24.00) while maintaining a Overweight rating.Analyst Charles ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login